Globally, there is a huge unmet need for effective treatments for neurodegenerative
diseases. The complexity of the molecular mechanisms underlying neuronal degeneration …

In neurological diseases, the actions of microglia, the resident myeloid cells of the CNS
parenchyma, may diverge from, or intersect with, those of recruited monocytes to drive …

Introduction Global estimates on numbers of persons in early stages of Alzheimer's disease
(AD), including prodromal and preclinical, are lacking, yet are needed to inform policy …

Two anti-amyloid monoclonal antibodies (MABs)—lecanemab (Leqembi®) and
aducanumab (Aduhelm®)—have been approved in the USA for the treatment of Alzheimer's …

Background Given the projected trends in population ageing and population growth, the
number of people with dementia is expected to increase. In addition, strong evidence has …

Background There is no simple model to screen for Alzheimer's disease, partly because the
diagnosis of Alzheimer's disease itself is complex—typically involving expensive and …

Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes
decades before the onset of clinical symptoms, enabling testing of interventions in the …

A growing body of evidence suggests that dysbiosis of the human gut microbiota is
associated with neurodegenerative diseases like Alzheimer's disease (AD) via …

The ability to investigate therapeutic interventions in animal models of neurodegenerative
diseases depends on extensive characterization of the model (s) being used. There are …

Alzheimer's disease (AD) dementia refers to a particular onset and course of cognitive and
functional decline associated with age together with a particular neuropathology. It was first …